Guselkumab treatment modulates genes differentially expressed in blood samples of patients with psoriatic arthritis vs healthy controls in two phase 3 clinical trials (DISCOVER-1 and-2)

被引：0
|
作者：
Siebert, Stefan [1 ]
Sweet, Kristen M. [2 ]
Ritchlin, Christopher T. [3 ]
Hsia, Elizabeth C. [4 ]
Kollmeier, Alexa P. [5 ]
Yang, Ya-Wen [6 ]
Xu, Xie L. [4 ]
Song, Qingxuan
Miron, Michelle [5 ]
机构：
[1] Univ Glasgow, Inst Infect, Stefan Siebert, Immun, Glasgow, Scotland
[2] Janssen Res Dev LLC, Spring House, San Deigo, PA USA
[3] Univ Rochester Med Ctr, Rochester, NY USA
[4] Res Dev LLC, Spring House, CA USA
[5] Janssen Res Dev LLC, Kollmeier, Spring House, CA USA
[6] Immunol Global Med Affairs, Janssen Pharmaceut Companies Johnson Johnson, Horsham, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
32938
引用
收藏
页码：AB170 / AB170
页数：1
相关论文
共 42 条
  • [1] GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND-2)
    Siebert, S.
    Sweet, K.
    Ritchlin, C. T.
    Hsia, E. C.
    Kollmeier, A.
    Xu, X. L.
    Song, Q.
    Miron, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 312 - 312
  • [2] Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and-2)
    Siebert, Stefan
    Sweet, Kristen
    Ritchlin, Christopher
    Hsia, Elizabeth
    Kollmeier, Alexa
    Xu, Xie
    Song, Qingxuan
    Miron, Michelle
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2795 - 2797
  • [3] Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials
    Siebert, Stefan
    Sweet, Kristen M.
    Ritchlin, Christopher T.
    Hsia, Elizabeth C.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Seridi, Loqmane
    Song, Qingxuan
    Gao, Sheng
    Chen, Warner
    Miron, Michelle
    [J]. ACR OPEN RHEUMATOLOGY, 2023, 5 (09) : 490 - 498
  • [4] Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials
    Ritchlin, Christopher T.
    Rahman, Proton
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    McInnes, Iain
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Shawi, May
    Zhou, Bei
    Mease, Philip J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB151 - AB151
  • [5] Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and-2 Randomized Clinical Trials
    Mease, Philip
    Korotaeva, Tatiana
    Shesternya, Pavel
    Kokhan, Muza
    Rukavitsyn, Anton
    Vasilchenkov, Dmitry
    Sharaf, Mohamed
    Lavie, Frederic
    Deodhar, Atul
    [J]. RHEUMATOLOGY AND THERAPY, 2024,
  • [6] Guselkumab, an anti-interleukin-23p19 monoclonal antibody, modulates core psoriatic arthritis gene expression in two phase III clinical trials (DISCOVER-1 and DISCOVER-2)
    Siebert, S.
    Sweet, K. M.
    Ritchlin, C. T.
    Hsia, E. C.
    Kollmeier, A. P.
    Xu, X. L.
    Song, Q.
    Miron, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E14 - E15
  • [7] Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
    Siebert, Stefan
    McInnes, Iain
    Loza, Matthew J.
    Ma, Keying
    Leander, Karen
    Lakshminarayanan, Vani
    Franks, Carol
    Cooper, Philip
    Sweet, Kristen
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [8] GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)
    Siebert, S.
    Mcinnes, I.
    Loza, M. J.
    Ma, K.
    Leander, K.
    Lakshminarayanan, V.
    Franks, C.
    Cooper, P.
    Sweet, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 144 - 145
  • [9] Efficacy of guselkumab using composite endpoints in patients with active psoriatic arthritis: Domain-specific efficacy from DISCOVER-1 and DISCOVER-2 phase 3 trials
    Coates, Laura C.
    Ritchlin, Christopher T.
    Gossec, Laure
    Helliwell, Philip S.
    Rahman, Proton
    Kollmeier, Alexa P.
    Karyekar, Chetan
    Sheng, Shihong
    Agarwal, Prasheen
    Mease, Philip J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB127 - AB127
  • [10] Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
    Mease, Philip J.
    Helliwell, Philip S.
    Gladman, Dafna D.
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Sweet, Kristen
    Shawi, May
    Karyekar, Chetan S.
    Deodhar, Atul
    van der Heijde, Desiree
    [J]. LANCET RHEUMATOLOGY, 2021, 3 (10): : E715 - E723
12345